Drug intelligence / Profile preview

DWC202405

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC202405 is an investigational pharmaceutical drug being evaluated for the treatment of essential hypertension. It is currently in phase III clinical trials, where its efficacy and safety are being assessed both as monotherapy and in combination with other agents (DWC202313 and DWC202314) in patients whose hypertension is inadequately controlled with DWC202405 alone. The developer of this drug is Daewoong Pharmaceutical. The precise mechanism of action has not been disclosed publicly, but it is under active investigation for antihypertensive effects.

Other names: DWC-202405DWC202405DWC 202405

Beyond the preview

Go deeper on DWC202405.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202405.

Explore the full profile